Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. The company operates in a single segment with principal product lines including thoracic and abdominal stent grafts, anastomotic clips, and vascular grafts. Operations are headquartered in Burlington, Massachusetts, with international offices in Germany, Italy, and Japan.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|
| Net Sales | $12,739 | $24,586 | $20,198 |
| Gross Profit | $8,886 | $17,375 | $14,983 |
| Gross Margin | 69.8% | 70.7% | 74.2% |
| Operating Loss | $(869) | $(3,454) | $(1,425) |
| Net Loss | $(926) | $(3,489) | $(402) |
| Cash and Cash Equivalents | $10,648 | $10,648 | $12,474 |
| Marketable Securities | $7,623 | $7,623 | $16,198 |
| Total Current Assets | $37,524 | $37,524 | $41,766 |
| Total Current Liabilities | $8,485 | $8,485 | $10,045 |
| Long-Term Debt | $45 | $45 | $42 |
Liquidity: As of June 30, 2008, the company held $18.3 million in combined cash, cash equivalents, and marketable securities. The company maintains a $10.0 million revolving line of credit with no outstanding balance as of the reporting date.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 23% for the quarter and 22% year-to-date compared to the prior year. Growth was driven by favorable foreign currency fluctuations, the inclusion of acquired Biomateriali products, and higher average selling prices.
- Margin Compression: Gross margin decreased from 74.2% to 70.7% year-to-date. This decline is attributed to the inclusion of lower-margin sales from the Biomateriali subsidiary and the distribution of the Powerlink System, partially offset by higher selling prices.
- Operating Expenses: Operating expenses increased significantly due to restructuring charges ($0.98 million for the six months) and impairment charges ($0.48 million). Restructuring costs included $0.6 million for distributor termination agreements and $0.4 million for severance related to a reduction in force of 32 employees.
- Net Loss Expansion: The net loss widened to $3.49 million for the six months ended June 30, 2008, compared to a loss of $0.4 million in the prior year period. This was exacerbated by a shift from a tax benefit in 2007 to a tax provision in 2008.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to fund operations for at least the next 12 months using existing cash and marketable securities. However, future capital requirements for acquisitions or growth may necessitate additional equity or debt financing.
- Unusual Items:
- Impairment Charges: Recorded $0.435 million in January 2008 due to a customer discontinuing purchases of a Biomateriali product line, and $0.048 million in June 2008 for patents deemed to have no future economic value.
- Restructuring: Incurred $0.98 million in charges related to the termination of an Italian distributor and workforce reductions.
- Risks and Contingencies:
- Internal Controls: The company identified a material weakness in internal controls over financial reporting regarding accruals and reconciliation procedures. While remediation steps (hiring new personnel, training) are underway, management concluded that disclosure controls were not effective as of June 30, 2008.
- Regulatory Issues: The FDA issued a Warning Letter in June 2008 regarding deficiencies in the conduct of the UniFit Abdominal Stent Graft clinical trial. The company has submitted corrective actions, but future inspections may impact the trial.
- Acquisition Disputes: The company has filed indemnity claims against the sellers of Biomateriali totaling approximately $1.1 million regarding undisclosed customer relationship issues and inventory matters. Post-closing payments have been withheld pending resolution.
- NASDAQ Compliance: Following the resignation of a director, the company no longer met the requirement for a majority of independent directors on its board. It has until July 24, 2009, to cure this deficiency to avoid potential delisting.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of hiring and training initiatives to address the material weakness in financial reporting controls.
- Regulatory Status: Monitor the FDA's response to the corrective action plan regarding the UniFit clinical trial and the status of the TAArget feasibility study application.
- Acquisition Integration: Assess the financial impact of the Biomateriali acquisition, specifically the resolution of the $1.1 million indemnity claim and the stability of the Sorin Biomedica customer relationship.
- Liquidity Position: Track cash burn rates given the negative operating cash flow of $3.2 million for the six-month period and the potential need for future capital raises.
- NASDAQ Compliance: Confirm the appointment of new independent directors to satisfy NASDAQ listing requirements before the cure period expires.